EverSource Wealth Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

EverSource Wealth Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-868	Closed	-$2K	–	2181
2022 Q2	$2K	Buy	+868	New	+$1.89K	﹤0.01%	1602
2022 Q1	–	Sell	-573	Closed	-$3K	–	1897
2021 Q4	$3K	Buy	+573	New	+$2.72K	﹤0.01%	1479

Other funds holding PRTK

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return

EverSource Wealth Advisors's PRTK Position: Q3 2022 in Review

EverSource Wealth Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2022, closing a stake of 868 shares — an estimated $2K sold.

EverSource Wealth Advisors first reported a position in PRTK in Q4 2021 and held it in 2 quarters. The position peaked at $3K in Q4 2021. 72 funds tracked by Wall St. Rank hold PRTK as of Q3 2022.

EverSource Wealth Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
EverSource Wealth Advisors sold 868 Paratek Pharmaceuticals, Inc. shares in Q3 2022, an estimated $2K.
EverSource Wealth Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2021 and held it in 2 quarters.
EverSource Wealth Advisors's Paratek Pharmaceuticals, Inc. position peaked at $3K in Q4 2021.
72 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2022.

Based on EverSource Wealth Advisors's 13F filing for Q3 2022, filed 7 Nov 2022.